Oct 24 (Reuters) - Eli Lilly and Co, one of the world's top insulin-makers, on Tuesday reported a better than expected third-quarter profit, and said it was reviewing options, including a sale or an ...
Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.
Eli Lilly and Co. has attracted interest from private equity firms including Bain Capital and Advent International Corp. for its Elanco animal-health business, as the pharmaceutical giant considers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results